Acadian Asset Management’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-3,253
Closed -$34K 2011
2026
Q1
$34K Buy
+3,253
New +$31.7K ﹤0.01% 1894
2024
Q1
Sell
-18,087
Closed -$1.66M 1588
2023
Q4
$1.66M Sell
18,087
-3,418
-16% -$347K 0.01% 722
2023
Q3
$3.55M Buy
21,505
+4,140
+24% +$538K 0.01% 540
2023
Q2
$1.1M Buy
17,365
+6,298
+57% +$382K ﹤0.01% 860
2023
Q1
$374K Sell
11,067
-9,636
-47% -$503K ﹤0.01% 1122
2022
Q4
$1.19M Buy
+20,703
New +$1.28M 0.01% 803
2021
Q1
Sell
-65
Closed -$92K 2085
2020
Q4
$92K Buy
+65
New +$69.3K ﹤0.01% 1776
2020
Q2
Sell
-14
Closed -$5K 2231
2020
Q1
$5K Sell
14
-29
-67% -$20.5K ﹤0.01% 1737
2019
Q4
$27K Sell
43
-576
-93% -$282K ﹤0.01% 1689
2019
Q3
$207K Hold
619
﹤0.01% 1313
2019
Q2
$161K Buy
+619
New +$124K ﹤0.01% 1277

Other funds holding CDLX

Acadian Asset Management's CDLX Position: Q2 2026 in Review

Acadian Asset Management sold out of Cardlytics (CDLX) in Q2 2026, closing a stake of 3,253 shares — an estimated $34K sold.

Acadian Asset Management first reported a position in CDLX in Q2 2019 and held it in 11 quarters. The position peaked at $3.55M in Q3 2023. 42 funds tracked by Wall St. Rank hold CDLX as of Q2 2026.

  • Acadian Asset Management reported no remaining Cardlytics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 3,253 Cardlytics shares in Q2 2026, an estimated $34K.
  • Acadian Asset Management first reported a position in Cardlytics in Q2 2019 and held it in 11 quarters.
  • Acadian Asset Management's Cardlytics position peaked at $3.55M in Q3 2023.
  • 42 funds tracked by Wall St. Rank held Cardlytics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.